Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
Alberto F. Sobrero(Ospedale Policlinico San Martino), Qian Shi(Mayo Clinic), Ioannis Boukovinas, Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Jeffrey A. Meyerhardt(CancerCare), Andrea Harkin(Queen's University Belfast), Mark Saunders(Manchester Academic Health Science Centre), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Axel Grothey(Campbell Clinic), Takayuki Yoshino(University of Tsukuba), Eiji Oki(Kyushu University), Ioannis Sougklakos(University Hospital of Heraklion), Anthony F. Shields(Wayne State University), Thierry André(Inserm), Roberto Labianca(Ospedale Papa Giovanni XXIII), Vassilis Georgoulias(Metropolitan College), Déwi Vernerey(Inserm), Takeharu Yamanaka(National Cancer Center Hospital East), Jeffrey P. Meyers(Mayo Clinic in Florida), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 36
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k